Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in heart transplant patients with CAV
NCT03944577Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in Cardiac allograft vasculopathy (CAV), hypercholesterolemia, sponsored by University of Nebraska. Started Jul 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
Cardiac allograft vasculopathy (CAV)hypercholesterolemia
Beyond the preview
Go deeper on NCT03944577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944577.